Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
INDOCO REMEDIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
INDOCO REMEDIES Mar-23 |
ADCOCK INGRAM Jun-14 |
INDOCO REMEDIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 423 | 327 | - | |
Low | Rs | 308 | 236 | - | |
Sales per share (Unadj.) | Rs | 181.1 | 97.3 | - | |
Earnings per share (Unadj.) | Rs | 15.4 | -24.5 | - | |
Cash flow per share (Unadj.) | Rs | 23.1 | -20.3 | - | |
Dividends per share (Unadj.) | Rs | 2.25 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 111.5 | 76.3 | - | |
Shares outstanding (eoy) | m | 92.15 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.0 | 2.9 | 69.8% | |
Avg P/E ratio | x | 23.7 | -11.5 | -206.2% | |
P/CF ratio (eoy) | x | 15.8 | -13.9 | -114.2% | |
Price / Book Value ratio | x | 3.3 | 3.7 | 88.9% | |
Dividend payout | % | 14.6 | 0 | - | |
Avg Mkt Cap | Rs m | 33,683 | 47,499 | 70.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3,226 | 2,981 | 108.2% | |
Avg. sales/employee | Rs Th | 0 | 3,824.0 | - | |
Avg. wages/employee | Rs Th | 0 | 694.4 | - | |
Avg. net profit/employee | Rs Th | 0 | -963.6 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 16,686 | 16,416 | 101.6% | |
Other income | Rs m | 24 | 115 | 20.7% | |
Total revenues | Rs m | 16,710 | 16,531 | 101.1% | |
Gross profit | Rs m | 2,860 | -2,845 | -100.5% | |
Depreciation | Rs m | 706 | 709 | 99.7% | |
Interest | Rs m | 250 | 445 | 56.3% | |
Profit before tax | Rs m | 1,928 | -3,883 | -49.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 505 | 243 | 208.3% | |
Profit after tax | Rs m | 1,423 | -4,137 | -34.4% | |
Gross profit margin | % | 17.1 | -17.3 | -98.9% | |
Effective tax rate | % | 26.2 | -6.2 | -419.5% | |
Net profit margin | % | 8.5 | -25.2 | -33.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 8,082 | 12,024 | 67.2% | |
Current liabilities | Rs m | 4,245 | 6,765 | 62.8% | |
Net working cap to sales | % | 23.0 | 32.0 | 71.8% | |
Current ratio | x | 1.9 | 1.8 | 107.1% | |
Inventory Days | Days | 25 | 111 | 22.6% | |
Debtors Days | Days | 768 | 124 | 619.4% | |
Net fixed assets | Rs m | 9,055 | 7,009 | 129.2% | |
Share capital | Rs m | 184 | 76 | 241.8% | |
Net worth | Rs m | 10,276 | 12,885 | 79.8% | |
Long term debt | Rs m | 1,435 | 4,528 | 31.7% | |
Total assets | Rs m | 17,137 | 24,341 | 70.4% | |
Interest coverage | x | 8.7 | -7.7 | -112.6% | |
Debt to equity ratio | x | 0.1 | 0.4 | 39.7% | |
Sales to assets ratio | x | 1.0 | 0.7 | 144.4% | |
Return on assets | % | 9.8 | -15.2 | -64.4% | |
Return on equity | % | 13.8 | -32.1 | -43.1% | |
Return on capital | % | 18.6 | -19.8 | -93.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,788 | 1,401 | 127.6% | |
From Investments | Rs m | -2,082 | -430 | 483.8% | |
From Financial Activity | Rs m | 228 | 4,110 | 5.5% | |
Net Cashflow | Rs m | -65 | 5,081 | -1.3% |
Compare INDOCO REMEDIES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare INDOCO REMEDIES With: COLINZ LABOR ALBERT DAVID SUVEN LIFE SCIENCES BACIL PHARMA GANGA PHARMACEUTICALS
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.